A brief review of fluconazole as an antifungal agent and the need for research into its nanoformulation

Author:

Nagaraj S.1

Affiliation:

1. Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamilnadu, 603103, India

Abstract

Antifungals compounds have gained significant attention, and in this context, fluconazole as an antifungal is used predominantly, and the use of a nanoformulated form of this is discussed. Fluconazole, an FDA-approved antibiotic, is an effective antimicrobial especially used to treat fungal infections. Its uniqueness lies in the fact that it contains fluoride with triazole functionality. Its efficacy against various types of fungus is demonstrated. Although it is one of the effective antibiotics, its side effects are well documented, and due to this, many techniques are tried to improve its efficacy with lesser side effects. In this respect, nanoparticles play a crucial role, and many studies worldwide are carried out on this aspect. Among many nano techniques use of chitosan as well as lipid carriers of fluconazole are being considered. However, systematic studies are warranted to take this aspect into clinical trials. Nano-based platforms seem to be an alternating hope to combat resistance and side effect. A thorough study is the need of the hour to devise a proper nano-based strategy of fluconazole.

Publisher

Index Copernicus

Subject

Industrial and Manufacturing Engineering,Mechanics of Materials,General Materials Science

Reference25 articles.

1. L. Ostrosky-Zeichner, J.H. Rex, Chapter 53 - Antifungal and Antiviral Therapy, in: J.E. Parrillo, R.P. Dellinger (eds), Critical Care Medicine (Third Edition), Mosby, Philadelphia, 2008, 1089-1109. DOI: https://doi.org/10.1016/B978-032304841-5.50055-8

2. A.M.S. Alsaad, Y.C. Kaplan, G. Koren, Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis, Reproductive Toxicology 52 (2015) 78-82. DOI: https://doi.org/10.1016/j.reprotox.2015.02.009

3. J.H. van Burik, W. Leisenring, D. Myerson, R.C. Hackman, H.M. Shulman, G.E. Sale, R.A. Bowden, G.B. McDonald, The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients, Medicine 77/4 (1998) 246-254. DOI: https://doi.org/10.1097/00005792-199807000-00003

4. C.A. Kauffman, P.G. Pappas, D.S. McKinsey, R.A. Greenfield, J.R. Perfect, G.A. Cloud, C.J. Thomas, W.E. Dismukes, Allergy NIo, Group IDMS, Treatment of Lymphocutaneous and Visceral Sporotrichosis with Fluconazole, Clinical Infectious Diseases 22/1 (1996) 46-50. DOI: https://doi.org/10.1093/clinids/22.1.46

5. B.T. Fisher, T. Zaoutis, C.C. Dvorak, M. Nieder, D. Zerr, J.R. Wingard, C. Callahan, D. Villaluna, L. Chen, H. Dang, A.J. Esbenshade, S. Alexander, J.M. Wiley, L. Sung, Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial, Journal of the American Medical Association 322/17 (2019) 1673-1681. DOI: https://doi.org/10.1001/jama.2019.15702

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3